Capital Fund Management S.A. Incyte Corp Call Options Transaction History

Capital Fund Management S.A.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $366,912 - $439,104	-6,400 Reduced 37.87%	10,500 $694,000
Q2 2024 Aug 13, 2024	SELL	$51.18 - $63.75 $736,992 - $918,000	-14,400 Reduced 46.01%	16,900 $1.02 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $3.98 Million - $4.69 Million	-70,400 Reduced 69.22%	31,300 $1.78 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $3.39 Million - $4.17 Million	65,000 Added 177.11%	101,700 $6.39 Million
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $2.12 Million - $2.42 Million	36,700 New	36,700 $2.12 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $328,590 - $453,492	5,400 New	5,400 $362,000
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $215,956 - $262,548	-2,600 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $243,256 - $303,160	2,600	2,600 $246,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.